Severe mental disorders like schizophrenia are a leading cause of disability in people in the prime years of their lives (aged 15 to 44 years). Relapse is a primary contributor to schizophrenia disease burden and is frequently attributed to medication noncompliance and inadequate doses. Currently, a patient?s neuroleptic dose is titrated to clinical response within recommended dose ranges. Use of unbiased biomarkers of efective neuroleptic treatment-response would greatly facilitate the identifcation of a person?s lowest efective dose to minimize unsafe side efects and improve compliance. Biomarkers may allow precisely tailored adjustments of neuroleptic dose to reduce relapse due to variable disease course.
Berserk 16
La Bipolaridad del Chocolate: Balanda de Una Fregona 02
Pack Edt: Gals. Vol 2 a 6
Pax Romana (cult Comics)